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ABSTRACT

Objective: The nonlesioned motor cortex (M1NL) is thought to be hyperexcitable in patients with
subacute or chronic stroke and offers a promising therapeutic target. However, whether M1NL
excitability behaves the same for subcortical and cortical strokes is unknown. The aim of the
present study was to determine whether cortical, or purely subcortical, strokes have a different
effect on M1NL excitability.

Methods: We looked for correlations between the Fugl-Meyer (FM) score and M1NL resting
motor threshold (RMTNL) in 34 stroke survivors classified according to lesion location
(cortico-subcortical or purely subcortical). In addition to the FM, the Wolf Motor Score and
motor power were measured.
Results: FM correlated with RMTNL for subcortical (r 5 0.82; p 5 0.001) but not for cortical
strokes (r 5 0.11; p 5 0.62). Likewise, Wolf Motor Score (r 5 20.62; p 5 0.03) and motor power
(r 5 0.64; p 5 0.023) were correlated with RMTNL for the subcortical group, but not for the
cortical group.
Conclusion: We show that the impact on M1NL depends on lesion location and conclude that
protocols aimed at reducing M1NL cortical excitability may be worth exploring for subcortical
but not for cortical stroke. Neurology® 2015;85:517–520
GLOSSARY
Cx 5 cortico-subcortical; FM 5 Fugl-Meyer; M1L 5 lesioned motor cortex; M1NL 5 nonlesioned primary motor cortex;
MEPNL 5 nonlesioned motor evoked potential; MP 5 motor power; MSO 5 maximum stimulator output; RMTL 5 lesioned
hemisphere resting motor threshold; RMTNL 5 nonlesioned hemisphere resting motor threshold; SC 5 subcortical; TCI 5
transcallosal inhibition; TOAST 5 Trial of Org 10172 in Acute Stroke Treatment; WMS 5 Wolf Motor Score.

Physical rehabilitation in the subacute or chronic phase after stroke can draw on a number of
tactics, one of which is to target motor areas of the nonlesioned hemisphere, including primary
motor cortex (M1NL). An example is the use of noninvasive brain stimulation to reduce M1NL
excitability.1–3
Evidence supporting this notion comes from transcranial magnetic stimulation studies of intracortical and interhemispheric inhibition that show that (1) M1NL can be overactive or disinhibited
and exert an excessive inhibitory drive to the lesioned motor cortex (M1L),4 and (2) noninvasive
brain stimulation of M1NL downregulating excitability can improve motor outcome.1,3 Furthermore, this hyperactivity is less apparent in chronic strokes exhibiting good motor recovery.5 It is
thought that interhemispheric cortico-cortical connectivity underlies these effects.6
However, given stroke variability, it is also accepted that a “one size fits all” approach to stroke
rehabilitation is not likely to be optimal.3 Accordingly, there is interest in identifying markers to
stratify therapeutic approaches after stroke.
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In the present study, we investigated the
relationship between M1NL excitability and
paretic hand function in patients with strokes
that involved motor cortex compared with
purely subcortical strokes. We hypothesized
that this relationship may differ between groups
because of differential effects of lesion location
on intra- and interhemispheric circuits.
METHODS We studied 34 stroke survivors satisfying the following criteria: right hand dominant; first-ever middle cerebral
artery ischemic stroke affecting the right upper limb; upper
extremity Fugl-Meyer (FM) 7–58; ability to follow instructions;
no fixed joint contracture at the upper limb; no history of
seizures; and no other neurologic conditions or implanted
devices. In addition to the FM, the Wolf Motor Score (WMS)
and motor power (MP) (Medical Research Council) were
measured in all participants. Stroke subtypes were classified
according to TOAST (Trial of Org 10172 in Acute Stroke
Treatment) criteria.7
Participants were classified into 2 groups according to neuroimaging as read by a clinical neuroradiologist. The corticosubcortical (Cx) group had lesions involving primary motor cortex that could extend to underlying white matter; the subcortical
(SC) group had deeper infarcts of the basal ganglia and internal
capsule (excluding cerebral cortex, brainstem, and cerebellum).
Nonlesioned (right hemisphere) resting motor threshold
(RMTNL) and resting motor evoked potential (MEPNL) amplitude were measured from the left flexor carpi radialis muscle using
transcranial magnetic stimulation (MagPro X100) and a figure-8
coil placed over the optimal stimulus site from initial exploration.
RMTNL was defined as the intensity (2% steps of maximum
stimulator output [MSO], ascending and descending order) that
elicited a response with .50 mV amplitude (peak-peak) in at least
5 of 10 stimuli. Resting MEPNL amplitude was averaged from 10
stimuli delivered at 120% RMTNL. In all participants, we also
explored the lesioned hemisphere to establish whether a MEP
could be recorded from the right flexor carpi radialis, in which
case RMTL was measured.
Between-group characteristics were compared with Student
t tests and a x2. We modeled the data with FM as the dependent
outcome, and site of lesion and RMTNL and the interaction term
between these 2 variables as independent variables. We conducted
post hoc correlational analysis (Pearson product-moment) between
clinical scores and neurophysiologic measures separately for Cx and
SC groups. Data are presented as mean 6 SD.

Standard protocol approvals, registrations, and patient
consents. All patients gave written informed consent to the
study, which was approved by the institutional review board of

Table 1

TSS, sex, and age at time of study for the Cx and SC groups

Group (no. of participants)

TSS, mo

Sex, M/F

Age, y

Cx (22)

54 6 34

12/10

65 6 9

SC (12)

71 6 6

6/6

76 6 5

p Value

0.29

0.8

0.0003

Abbreviations: Cx 5 cortico-subcortical; SC 5 subcortical; TSS 5 time since stroke.
Data are mean 6 SD or count. There was a between-group significant difference in age but
not TSS or sex.
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the Burke Rehabilitation Hospital. See table 1 and table e-1 on
the Neurology® Web site at Neurology.org.

Of the 34 participants who met the inclusion criteria, 22 were categorized as Cx and 12 as SC.
Approximately half of the strokes (53%) had a TOAST
classification of 3 (small artery occlusion), 18% 2 (cardioembolism), and 18% 1 (large artery atherosclerosis)
(see table e-1). There was no between-group difference
in time since stroke (4.5 6 2.8 vs 6 6 0.5 years) or
sex; however, the mean age of the SC group was greater
than for the Cx group (76 6 5 vs 65 6 9 years of age;
p 5 0.0003; table 1). Clinical scores (FM, WMS, MP)
and RMTNL were not significantly different between
groups (table 2).
The between-group FM and RMTNL interaction
term was significant (r 5 0.25; p 5 0.024). The interaction remained significant (p 5 0.028) when age was
added to the model to allow for the between-group age
difference.
We investigated the interaction further by correlation
analysis. There was a significant correlation between FM
and RMTNL for the SC group (r 5 0.82; p 5 0.001) but
not for the Cx group (r 5 0.11; p 5 0.62; figure, A).
We examined the relationship between RMTNL
and the remaining clinical scores in an exploratory
manner. Both WMS (r 5 20.62; p 5 0.03) and
MP (r 5 0.64; p 5 0.023) were correlated with
RMTNL for the SC group but not for the Cx group
(figure, B and C).
There was no significant interaction or correlation
between MEPNL and clinical variables for either the
SC or the Cx group. For the lesioned hemisphere,
RMTL could not be determined (i.e., .MSO) in
the majority of participants in both groups (16, Cx;
11, SC).
RESULTS

DISCUSSION There was no significant difference in
M1NL excitability or clinical scales between Cx and
SC strokes; rather, it was the relationship between
these parameters that was strikingly different between
groups and correlated only for SC. Increased impairment (as determined by FM), decreased function
(WMS), and reduced power (MP) were associated
with reduced RMTNL and thus greater M1NL excitability for patients with SC. This relationship was not
observed for lesions involving motor cortex. The results indicate that the excitability of the nonlesioned
hemisphere after stroke is related to the anatomical
level of the lesion and to the degree of paretic motor
function or impairment.
Interhemispheric excitability effects are widely
attributed to reciprocal transcallosal inhibition
(TCI) between motor cortices.2 Strokes involving
motor cortex could disrupt TCI depending on how
the lesion affects intra- or perilesional connections or
callosal fibers.8 However, cortical lesions extending
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Table 2

Cx

FM, WMS, MP, and RMTNL for the Cx and SC groups
FM

WMS

MP

RMTNL

19.8 6 12.9

1,046 6 679

262

50.8 6 18.3

SC

21.9 6 16.2

988 6 815

2.6 6 1.9

58.3 6 22.9

p Value

0.86

0.82

0.37

0.3

Abbreviations: Cx 5 cortico-subcortical; FM 5 Fugl-Meyer; MP 5 motor power; RMTNL 5 nonlesioned hemisphere resting motor threshold; SC 5 subcortical; WMS 5 Wolf Motor Score.
Data are mean 6 SD. There were no significant differences between groups.

into underlying white matter could differentially
affect descending corticospinal conduction compared
with transcallosal conduction. In this situation,
M1NL excitability would not necessarily be related
to paretic hand function, which is in keeping with
our findings, although we cannot rule out that there

Figure

may be a subgroup of cortical strokes (e.g., sparing
transcallosal conduction) in which this relationship
holds.
While lesions in the SC group did not extend to
M1L, they could still exert a remote effect, for example,
secondary to reduced sensorimotor afference or alterations in corticomotor drive, while leaving TCI functionally and anatomically intact. Our results in the SC
group can be explained if the effect of the lesion is to
downregulate M1L excitability and if a greater impairment results in a greater reduction. The ensuing withdrawal of inhibitory drive from M1L to M1NL could
thus result in an increase in excitability that is in proportion to the impairment. This explanation is in keeping with recent models of functional diaschisis.9
While clinical scales correlated with RMTNL for
SC stroke, there was no correlation in either group

Relationship between paretic upper limb clinical grades

(A) Fugl-Meyer; (B) Wolf Motor Score; (C) motor power, and resting motor threshold measured over the nonlesioned hemisphere for each participant with subcortical and cortico-subcortical strokes. There were significant correlations between
the clinical grades and resting motor threshold for subcortical stroke but not for cortico-subcortical stroke.
Neurology 85
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with MEPNL, presumably because stimulus intensity
was threshold-adjusted (120% RMTNL) for recording the MEP, thus partially correcting for excitability
differences. We did not attempt to record interhemispheric effects with paired-pulse protocols8 because
RMTL was greater than MSO in the majority of
participants (27/34).
Detailed tractography was beyond the scope of the
present study; however, it is likely that Cx lesions resulting in hand paresis involved M1 and therefore the
gray matter origin of the transcallosal pathway and
could also extend into underlying white matter to disrupt transcallosal axons. It might have been expected
that damage to transcallosal conduction in Cx compared with SC patients would then lead to a
between-group difference in RMTNL. It is possible
that the dispersion in RMTNL between patients has
obscured an intergroup difference or that factors in
addition to transcallosal disinhibition contribute to
RMTNL. The only significant intergroup difference
was age, which could potentially modulate corticomotor excitability. However, we found that the relationship between FM and RMTNL remained
significant when age was added to the model.
The close relationship between excitability and
impairment for SC strokes suggests that patients with
SC strokes may be the best candidates for therapeutic
approaches aimed at reducing M1NL excitability.
However, it is also possible that M1NL hyperexcitability is secondary to the impairment and not a driving
force, and that as recovery proceeds, excitability correspondingly normalizes.5 In this case, there may be
little to be gained by targeting M1NL. Given these
considerations, clinical trials may want to stratify by
lesion location and consider patients with Cx and SC
strokes separately.10,11
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